drugset / Trial / NCT01963325
S-1 in Combination With Abraxane in Treating Cholangiocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This phase II study was designed to evaluate the efficacy and safety of S-1 plus Abraxane as second-line treatment for cholangiocarcinoma.
Timeline
- Start
- 2013-08
- Primary completion
- 2017-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abraxane | Small molecule | 100 mg/m2 | — |
| Subject | S-1 | Small molecule | 80 mg | Oral |
| Subject | S-1 | Small molecule | 100 mg | Oral |
| Subject | S-1 | Small molecule | 120 mg | Oral |